Alexander Rudensky’s research has defined regulatory T cells and the roles they play in autoimmunity, tolerance, allergies, infections, and cancer. After completing his PhD in Moscow in the early 1980s, Rudensky moved to the United States to study T cells under the mentorship of Charles Janeway. He is currently a professor of immunology at the Memorial Sloan Kettering Cancer Center. JCI Editor at Large Ushma Neill interviews Dr. Rudensky about his childhood in the Soviet Union and his early interest in mathematics and science. He discusses the mentors and coworkers who have shaped his research interests over time, and speculates about the immunological discoveries we can expect in years to come.
Laurie Glimcher is a world-class immunologist who discovered the master transcription factors that direct immune cells to commit and activate. She has also discovered a key anabolic bone pathway and become an expert on ER stress and lipoprotein production. Most recently, Glimcher discovered a critical signaling pathway in both tumor cells and host immune responses. All the while, she’s acted as an academic leader, at Harvard School of Public Health and as dean of Weill Cornell Medical School, and she is about to take the reins of the Dana-Farber Cancer Institute as President and CEO.
Bert Vogelstein, MD, and Kenneth Kinzler, PhD, are codirectors of the Ludwig Center at the Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins University School of Medicine. Vogelstein and Kinzler demonstrated that colorectal cancer results from the sequential accumulation of mutations in oncogenes and tumor suppressor genes, establishing a paradigm for modern cancer genomics. Additionally, they discovered the tumor suppressors APC and TP53; they were the first to perform exomic sequencing in tumors; and they developed digital PCR. In an interview with JCI’s Editor-at-Large Ushma Neill, Vogelstein and Kinzler reflect on their career trajectories and past discoveries and discuss their goals as scientists.
Dr. Huda Zoghbi is a pediatric neurologist, a Howard Hughes Medical Institute investigator; a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine; and the founding director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital. Her work has focused on elucidating the mechanisms underlying Rett syndrome and spinocerebellar ataxia. In an interview with JCI Editor-at-Large Ushma Neill, Dr. Zoghbi describes her childhood in Beirut, Lebanon. After her medical studies were interrupted by Lebanon’s civil war, Dr. Zoghbi enrolled at Meharry Medical College. She became interested in pediatric neurological disorders during her residency, when she observed many patients with devastating disorders that appeared to have underlying genetic causes. Dr. Zoghbi also describes her discovery of a genetic cause of Rett syndrome, a null mutation in the methyl-CpG binding protein 2 (MeCP2), which researchers are now trying to target therapeutically.
James Allison of the MD Anderson Cancer Center has made key discoveries on the regulation of T cell activation and modulation, including identification and characterization of the T cell antigen receptor and the T cell coreceptors CD28 and cytotoxic T lymphocyte antigen-4 (CTLA-4). He was awarded the 2015 Lasker~DeBakey Clinical Medical Research Award in honor of his discovery and subsequent development of CTLA-4–targeted monoclonal antibody therapy to unleash the immune response to cancer. In an interview with JCI Editor at Large Ushma Neill, Allison discusses his decision to pursue a PhD instead of an MD and his early experiences in applying biochemical techniques to immunological questions. Additionally, Allison talks about the process of moving anti–CTLA-4 therapy into the clinic.